News >

Obinutuzumab and Bendamustine Combo Shows Encouraging Activity in Upfront CLL

Wayne Kuznar
Published: Thursday, Jul 13, 2017

Jeff P. Sharman, MD

Jeff P. Sharman, MD

The anti-CD20 monoclonal antibody obinutuzumab (Gazyva) combined with bendamustine (Treanda; BG) in the frontline setting for patients with chronic lymphocytic leukemia was found to induce high rates of complete response (CR) and minimal residual disease (MRD) negativity with no unexpected safety signals, according to results from a phase II open-label, multicenter study.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication